The plant will manufacture Clariant’s moisture-control products to support the growing pharmaceutical packaging market in India.Clariant announced on Dec. 1, 2015 that it is investing CHF 10 million in a new packaging manufacturing plant in Cuddalore, India. The plant will manufacture Clariant’s moisture-control products to support the growing pharmaceutical packaging market in India.
Clariant announced on Dec. 1, 2015 that it is investing CHF 10 million in a new packaging manufacturing plant in Cuddalore, India. The plant will manufacture Clariant’s moisture-control products to support the growing pharmaceutical packaging market in India.
The company recognizes India’s position as the largest generic-drug producer. Ketan Premani, head of Clariant Healthcare Packaging Sales in India, commented in a press release this makes India a key market for Clariant’s desiccant products. The new Cuddalore plant will serve branded and generic drug companies operating in India as well as domestic players.
Clariant Healthcare Packaging, a member of Business Unit Masterbatches, manufactures a range of controlled atmosphere packaging solutions including pharmaceutical desiccants, equilibrium sorbents, adsorbent polymers, oxygen scavengers, and pharmaceutical closures and containers. The Cuddalore plant will initially produce desiccant canisters and packets, which are inserted into pharmaceutical packaging to control moisture and protect the stability of the medicine during shelf life. The desiccant production area will be clean room Class 100,000 and certified ISO 8. It will be compliant with all relevant cGMP and US FDA standards. â¨
Source: Clariant
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Telix Enters Agreement with ImaginAb to Purchase Next-Gen Therapeutic Candidates
Published: January 13th 2025 | Updated: January 13th 2025The transaction adds a pipeline of early-stage drug candidates against high-value targets to Telix’s portfolio, along with other novel targets currently in the discovery stage.